NEW YORK, April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).Shareholders who purchased shares of GERN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=140405&from=4CLASS PERIOD: February 28, 2024 ...

SAN DIEGO, April 3, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025, both dates inclusive (the "Class Period"), have until Monday, May 12, 2025 to seek appointment as lead plaintiff of the Geron class action lawsuit.  Captioned Dabestani v. Geron Corporation, No. 25-cv-02507 (N.D. Cal.), the Geron class action lawsuit charges Geron and certain of Geron's ...

Core Viewpoint - Geron Corporation is facing a federal securities class action due to alleged failure to disclose material information regarding the launch and growth potential of its lead product candidate, Rytelo, during the specified Class Period [4]. Financial Performance - On February 26, 2025, Geron announced its fourth-quarter financial results for fiscal 2024, revealing that the growth of Rytelo had flattened in recent months. The company attributed this stagnation to seasonality, competition, lack of awareness, and monitoring requirements for the drug treatment [3]. - Following the announcement, Geron's share price dropped by $0.76, from $2.37 on February 25, 2025, to $1.61 on February 26, 2025 [3]. Legal Proceedings - A class action has been filed on behalf of investors who acquired Geron securities between February 28, 2024, and February 25, 2025, with a deadline of May 12, 2025, to seek the role of lead plaintiff [1]. - The complaint alleges that the defendants failed to disclose critical information regarding the expectations for Rytelo's launch and growth potential throughout the Class Period [4].

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our ...

RADNOR, Pa., March 31, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Geron Corporation ("Geron") (NASDAQ: GERN) on behalf of those who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is May 12, 2025. The complaints allege that, throughout the Class Period, Defendants made false a ...

Core Viewpoint - Geron Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the performance and market potential of its primary product, Rytelo [1][3]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on developing therapeutic products for oncology, with its main product being a telomerase inhibitor called imetelstat, marketed as Rytelo [2]. Allegations of the Lawsuit - The lawsuit alleges that Geron and its executives made false or misleading statements about the company's revenue outlook and growth potential, downplaying risks associated with seasonality and macroeconomic factors [3]. - It is claimed that the optimistic reports regarding Rytelo's launch success did not reflect the reality of its market penetration challenges, including competition and a lack of awareness among potential patients [3]. - Following the announcement of financial results for Q4 2024, which indicated stagnant growth for Rytelo, Geron's stock price dropped over 32%, highlighting the impact of the alleged misrepresentations [4]. Legal Process - Investors who purchased Geron securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Geron Corporation (NASDAQ: GERN) has experienced a potential plateau in the sales of its product Rytelo (imetelstat) shortly after its launch in mid-2025, which may be causing market concerns [1] Company Summary - Geron Corporation has only reported two full quarters of sales for Rytelo since its introduction [1] - The market appears to be reacting to the stagnation in sales growth following the product's launch [1]

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Geron Corporation (NASDAQ: GERN) securities between June 7, 2024 to February 25, 2025. Geron is a commercial-stage biopharmaceutical company with a focus on blood cancer. Geron's primary product is a telomerase inhibitor, imetelstat, which the Company sells under the brand name, Rytelo. Attorney Advertising. Past results do not guarantee ...

CONTACT US HERE: https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=139419&from=4 CLASS PERIOD: February 28, 2024 to February 25, 2025 ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning defendants' expectations for the launch and growth potential of Rytelo (imetelstat). Defendants' statements included, among other things, confidence in Geron's ability to capitalize on the purportedly significant unmet need for the dru ...

Kessler Topaz Meltzer & Check, LLP encourages Geron investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/geron- corporation?utm_source=PR&utm_medium=link&utm_campaign=gern&mktm=r ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: RADNOR, Pa., March 30, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action la ...